Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
The success of Moderna’s vaccine against Covid-19 is reason for the whole world to cheer. The results from an interim analysis of the trial data are remarkably similar to those of Pfizer/BioNTech just a week ago. Most people – Moderna says 94.5%, Pfizer said more than 90% – were protected from illness.
It’s fantastic news. It means the concept works. Pfizer’s results were not a flash in the pan. Both vaccines have been developed using a new technology that has never produced a licensed vaccine before, called messenger RNA (mRNA), which some hail as the future of all vaccines. It has the potential to deliver vaccines for all sorts of diseases cheaply and safely, enthusiasts say. And crucially for the time being, they are likely to help us out of the Covid pandemic.
The early results are very good. They show that 90 people got Covid who were not vaccinated with the vaccine, called mRNA-1273. Just five who got ill were among those in the trial who got the new jab. They also show that none of the 11 who became severely ill had received the experimental vaccine. And among the 95 were people who were over 65 and people from different ethnicities, so the vaccine looks as though it may protect those most at risk. Side-effects included a sore arm and fatigue and were mostly mild to moderate and short-lived.
www.theguardian.com
It’s fantastic news. It means the concept works. Pfizer’s results were not a flash in the pan. Both vaccines have been developed using a new technology that has never produced a licensed vaccine before, called messenger RNA (mRNA), which some hail as the future of all vaccines. It has the potential to deliver vaccines for all sorts of diseases cheaply and safely, enthusiasts say. And crucially for the time being, they are likely to help us out of the Covid pandemic.
The early results are very good. They show that 90 people got Covid who were not vaccinated with the vaccine, called mRNA-1273. Just five who got ill were among those in the trial who got the new jab. They also show that none of the 11 who became severely ill had received the experimental vaccine. And among the 95 were people who were over 65 and people from different ethnicities, so the vaccine looks as though it may protect those most at risk. Side-effects included a sore arm and fatigue and were mostly mild to moderate and short-lived.
Latest vaccine success is good news but high price may restrict access
Moderna results show Pfizer success was not flash in the pan, but poorer countries may have to look elsewhere
www.theguardian.com
